07 April 2014
SARAH CANNON RESEARCH INSTITUTE PRESENTS 10 CLINICAL TRIALS AT THE 105th ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH
NASHVILLE, TN, April 7, 2014 – Sarah Cannon Research Institute (SCRI) announced today that the American Association for Cancer Research (AACR) has selected 10 abstracts authored by SCRI investigators to be presented at the 2014 AACR Annual Meeting in San Diego. The meeting, which is being held April 5 – 9, brings together more than 18,000 researchers, patient advocates and other cancer professionals from around the world to discuss the latest in cancer research.
The annual conference highlights the increasing pace at which basic science is being translated into clinical advances for novel cancer treatments. SCRI’s presentations – including seven posters and three clinical symposiums – demonstrate the importance of early-phase trials in assessing the activity of targeted therapies.
“SCRI's experience in conducting more than 130 first-in-man trials enables us to provide unique insights into the evaluation of novel anti-cancer agents at the earliest stages” said Howard A. Burris III, MD, Chief Medical Officer. "We are proud to share our latest findings, which are helping to accelerate the development of these much needed therapies.”
Two of the company’s principal investigators are participating in clinical symposiums at the AACR Annual Meeting. SCRI’s Director of Drug Development, Jeffrey R. Infante, MD, will present a first-in-human phase I study of the safety and pharmacokinetic (PK) activity of DEDN6526A, an anti-endothelin B receptor (ETBR) antibody-drug conjugate (ADC), in patients with metastatic or unresectable melanoma. Johanna Bendell, MD, Director of GI Cancer Research for SCRI, will present clinical results of a phase Ib dose-escalation study of the Mek inhibitor cobimetinib (GDC-0973) and the Akt inhibitor ipatasertib (GDC-0068) in patients with solid tumors.
“The antibody drug conjugates are generating excitement by their targeted delivery of potent chemotherapies directly to cancer cells,” Infante said. “In reducing the toxicity to normal cells, we are hopeful patients will experience greater benefits and fewer side effects from their treatment.”
A full list of the abstracts can be downloaded from the link below:
<< Back to News